# Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

> **NCT07528898** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Pertuzumab
- **DRUG:** trastuzumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07528898
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-07
- **Final completion:** 2029-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07528898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07528898, "Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07528898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*